Evidence map›Paper›PMID 31807543›Full record

ArticleAnnals of translational medicine2019

Shuxuening injection protects against myocardial ischemia-reperfusion injury through reducing oxidative stress, inflammation and thrombosis.

Ruiying Wang, Min Wang, Jiahui Zhou, Tianyuan Ye, Xueheng Xie, Dong Ni, Jingxue Ye, Qiaoling Han, Caixia Di, Liang Guo and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Shuxuening injection, derived fromPharmaceutical biology · 2020
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ruiying WangKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Min WangKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Jiahui ZhouKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Tianyuan YeKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Xueheng XieHarbin University of Commerce, Harbin 150076, China.
Dong NiJilin Agricultural University, Changchun 130118, China.
Jingxue YeKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Qiaoling HanShiyao Yinhu Pharmaceutical Co., Ltd., Yuncheng 044000, China.
Caixia DiShiyao Yinhu Pharmaceutical Co., Ltd., Yuncheng 044000, China.
Liang GuoShiyao Yinhu Pharmaceutical Co., Ltd., Yuncheng 044000, China.
Guibo SunKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Xiaobo SunKey Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing 100193, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNMinistry of Education of the People's Republic of China · CNHarbin University of Commerce · CNJilin Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundShuxuening injection (SXNI) has a good effect on cardiovascular and cerebrovascular diseases. Here, our study aims to investigate whether SXNI have the protective effect on myocardial ischemia-reperfusion injury (MIRI) and elucidate the mechanism of SXNI's cardiac protection.

methodsIn this experiment, the coronary arteries of Sprague-Dawley (SD) rats were ligated for the induction of a MIRI model. TTC staining and haematoxylin-eosin (HE), as well as troponin I (TnI), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), creatine kinase (CK) and CK-MB levels, were used to detect the protective effect of SXNI. In rat cardiac tissue, superoxide dismutase, catalase, glutathione and malondialdehyde (MDA) activities and glucose-regulated protein 78 (GRP78), calreticulin (CRT), CCAAT/enhancer binding protein homologous protein (CHOP) and caspase-12 expression levels were detected. In rat serum, the levels of inflammatory factors, including high-sensitivity C-reactive protein, monocyte chemoattractant protein-1, tumour necrosis factor-α, interleukin-6 (IL-6) and IL-1β, were measured by Elisa. In the rat arterial tissue, Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) expression was measured by western blot. In the rat plasma, ELISA was used to assay the levels of coagulation and plasmin system indicators, including platelet activating factor, endothelin, tissue factor (TF), plasminogen inhibitor, thromboxane B2, plasma fibrinogen.

resultsThe results showed that SXNI can reduce the infarct size of myocardial tissue, decrease the myocardial enzyme and TnI levels and decrease the degree of myocardial damage compared with the model group. Additionally, SXNI can increase the activity of antioxidant enzymes, reduce the MDA level and decrease the GRP78, CRT, CHOP and caspase-12 expression levels. SXNI also decreased the levels of inflammatory cytokines in rat serum, lowered the level of procoagulant molecules in plasma and reduced the TLR4/NF-κB expression.

conclusionsSXNI has protective effect on MIRI mainly by inhibiting oxidative stress and endoplasmic reticulum stress (ERS), thereby regulating TLR4/NF-κB pathway to reduce inflammation, and lowing procoagulant-related factors levels to reduce the risk of thrombosis.

Indexed as

endoplasmic reticulum stress (ERS)inflammationoxidative stressShuxuening injection (SXNI)thrombosis

Identifiers

PMID31807543
PMCPMC6861815
OpenAlexW2981167130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.